Frederique Menzaghi Ph.D., Chief Scientific Officer, SVP-R&D at Cara Therapeutics, Inc. (CARA), sold 2,812 shares at $15.30 ($43K) on 2020-12-30, disclosed to the SEC on 2020-12-30.
Scheduled sale ($43k) by Chief Scientific Officer, SVP-R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CARA | SELL | 2023-03-07 | $132K | — | Filing → |
| CARA | SELL | 2022-12-23 | $40K | — | Filing → |
| CARA | SELL | 2022-04-05 | $21K | — | Filing → |